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Table 1 – Sensitivity proﬁle of 9 P. aeruginosa isolates
resistant to colistin.
Antimicrobial Sensitive (n-%) Resistant (n-%)
Amikacin 7-77, 78% 2-22, 23%
Gentamicin 5-55, 56% 4-44, 45%
Cefepima 5-55, 56% 4-44, 45%
Ciproﬂoxacin 4-44, 45% 5-55, 56%
Piperacillin-Tazobactam 3-33, 34% 5-55, 56%
Ampicillin-Sulbactam 0 9-100%
Imipenem 3-33, 34% 6-66, 67%
Meropenem 3-33, 34% 6-66, 67%
pneumoniae, producers of SPM-1, OXA-23 or KPC-2.5 Additionalear Editor,
ndiscriminate use of antimicrobials has caused the world-
ide emergence of multidrug resistant bacteria (MDR).
lucose non-fermenting Gram-negative bacilli (NF-GNB) that
how resistance to several antimicrobials, including colistin,
ave been reported. The highest rates of this type of resistance
ave been registered in Asia and Europe.1 This fact has created
roblems in therapy, since the colistin is used as last alterna-
ive to treat infections caused by MDR  bacteria.2 Pseudomonas
eruginosa is a skilful microorganism that causes severe oppor-
unistic infections in immunocompromised patients due to
ts metabolic versatility.3 Isolation of P. aeruginosa resistant
o almost all available antimicrobials is increasing in Inten-
ive Care Units (ICU), leading to an increase in the number
f healthcare-associated infections (HAI), signiﬁcantly inﬂu-
ncing morbidity, mortality, and high costs of treatment of
nfected patients.1
In a prospective study developed between August 2015 and
anuary 2016 we  isolated 293 NF-GNB of various clinical spec-
mens from patients admitted to a university hospital in the
entral region of Rio Grande do Sul, Brazil. Identiﬁcation and
ntimicrobials sensitivity test were performed through the
utomated system VITEK®2 (bioMérieux). Data were inter-
reted according to the document M100-S25 of the Clinical and
aboratory Standards Institute [CLSI, 2015], considering resistant
he isolated specimens which showed intermediate or resis-
ant colistin proﬁles.
From the 293 NF-GNB assessed in this study, only two gen-
ra were identiﬁed: 78.83% (231) P. aeruginosa and 21.16% (62)
cinetobacter spp. Colistin resistance was identiﬁed in nine
solated strains of P. aeruginosa (9/231-3,89%) and none in Acine-
obacter spp. The predominant age group of patients in whom
olistin-resistant strains were identiﬁed was 41–69 years old
77.77%); this age-range also showed expressive resistance to
arbapenems (66.67%) (Table 1).
Colistin-resistant P. aeruginosa were predominantly iso-
ated from clinical specimens obtained from soft tissues
3/9-33.33%) and respiratory (sputum and tracheal secretion
 2/9-22.22%) secretions. The hospital wards in which resis-
ant strains were initially identiﬁed were internal medicineCeftazidime 3-33, 34% 6-66, 67%
(2/9-22.23%), surgery (2/9-22.23%), recovery room (2/9-22.23%),
nephrology, adult ER, and ICU (1/9-11.11% each).
From the nine patients in whom colistin-resistant P.
Aeruginosa was isolated, three progressed to death due
to septicemia, four were oncologic patients under anti-
neoplastic and radiotherapy regimens, one post-kidney
transplant patient, two diabetes mellitus patients, and two
chronic smokers/alcoholics. Therefore, we ratify that patients’
immunodepression make them vulnerable to infections
caused by colistin-resistant microorganisms.
The extensive use of colistin in veterinary medicine to
treat gastrointestinal infections caused by Enterobacteriaceae
has contributed to chromosomal mutations mediated by  the
plasmid mcr-1 to codify resistance to colistin in Gram-negative
bacilli. Fernandes and colleagues reported on the evidence
of mcr-1 originated from Escherichia coli isolated from food of
animal origin in Brazil since 2012.4 This silent dissemination
of E. coli resistance mediated by this plasmid is having an
impact in Brazilian ICUs. The emergence and dissemination
of MDR bacteria associated with high rates of treatment fail-
ure have fostered the use of poliximins, the main therapeutic
option for the treatment of MDR infections, especially those
caused by P. aeruginosa,  Acinetobacter baumannii,  and Klebsiellastudies are being developed by our research group to iden-
tify the gene mcr-1 in isolated strains that show resistance to
colistin.
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